Print Print   Email Email

The investor pages that follow are your resource for financial information about Medivation, Inc.

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat critically ill patients with serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.

Recent Releases

Mar 3, 2010
Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program

Mar 2, 2010
Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Phase 3 Trial Results for Dimebon in Alzheimer's Disease

more »

Events

Mar 16, 2010
The ROTH 22nd Annual OC Growth Stock Conference

more »

Investor and Media Contacts

For Investors
investors@medivation.com

For Media
media@medivation.com